Research Article Details
| Article ID: | A19051 |
| PMID: | 26800495 |
| Source: | J Diabetes |
| Title: | Age at menarche is associated with the prevalence of non-alcoholic fatty liver disease later in life. |
| Abstract: | BACKGROUND: The aim of the present study was to investigate whether age at menarche is associated with non-alcoholic fatty liver disease (NAFLD) later in life. METHODS: The association between age at menarche and obesity, insulin resistance, and NAFLD after menopause was investigated in a cross-sectional study of 4128 postmenopausal Chinese women; NAFLD was diagnosed by hepatic ultrasound and information regarding age at menarche was collected using an interviewer-administered questionnaire. RESULTS: Women with age at menarche <15 years had higher prevalence of overweight/obesity, insulin resistance, and NAFLD compared with women with age at menarche 15-18 or >18 years. Logistic regression revealed that women with earlier menarche had a higher risk for the age-adjusted prevalence of overweight/obesity, insulin resistance, and NAFLD, whereas later menarche showed a weaker, but still significant, association with a lower prevalence of NAFLD. However, further adjustment for some variables and current body mass index (BMI) or homeostasis model assessment of insulin resistance (HOMA-IR) attenuated the association between later menarche and a lower prevalence of NAFLD. A decreasing trend in the risk of NAFLD was seen across increasing levels of age at menarche (age-adjusted Ptrend  < 0.001; multivariate-adjusted Ptrend  < 0.001; multivariate + current BMI-adjusted Ptrend  = 0.03; multivariate + HOMA-IR-adjusted Ptrend  = 0.06). CONCLUSION: Age at menarche is associated with the prevalence of NAFLD later in life, independent of BMI and insulin resistance. |
| DOI: | 10.1111/1753-0407.12379 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |